A Epidemiology Study to Estimate the Attack Rate of Respiratory Syncytial Virus Infection in Older Adults
- Conditions
- Respiratory Syncytial Virus Infections
- Registration Number
- JPRN-UMIN000037891
- Lead Sponsor
- Janssen Pharmaceutical K.K. R&D Clinical Science div. Infectious disease & Vaccine Clinical Development Dept.
- Brief Summary
Respiratory syncytial virus was reported as a major pathogen for respiratory infection and represents a significant burden in the Japanese elderly population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Not provided
-Participants received any experimental antiviral drugs or vaccines against respiratory syncytial virus (RSV) within 6 months prior to the signing Informed Consent Form (ICFs) - Participants who have acute respiratory disease (ARD) at the time of ICF and Week 0 (Baseline) at the discretion of the investigator - Participants with life expectancy less than 1 year - Participants unwilling to undergo nasopharyngeal swab procedures or with any physical abnormality which limits the ability to collect regular nasopharyngeal specimens - Participant who is not able to comply with study-related procedures,due to their mental status or severe clinical condition, based on clinical judgement of the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of Participants with Protocol Defined Respiratory Syncytial Virus (RSV)-Acute Respiratory Disease (ARD) Confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) during study period (up to Week 52)
- Secondary Outcome Measures
Name Time Method